Quinidine therapy in hospitalized patients with ventricular arrhythmias

Nathan H. Carliner, William G. Crouthamel, Michael L. Fisher, Marc A. Mugmon, Dean L. Vassar, Prem K. Narang, Gary D. Plotnick

Research output: Contribution to journalArticle

Abstract

Quinidine serum levels and pharmacokinetic data were assessed during steady state therapy with oral quinidine sulfate in 19 hospitalized patients who were being treated for ventricular arrhythmias. A new high performance liquid chromatography assay was employed. Four patients were studied both after the first dose of quinidine and at steady state, and the initial dose pharmacokinetic values were found not to be predictive of steady state. The mean half-life of quinidine was 4.5 hours, but there was wide individual variation. The elimination rate constant for quinidine was significantly lower in patients with echocardiographic evidence of left ventricular dilatation than in patients with normal echocardiographic left ventricular size. The average urinary excretion of quinidine was only 11.3%. The pharmacokinetic data in seven chronic alcoholic patients without clinical or laboratory evidence of hepatic insufficiency did not differ from the data obtained in nonalcoholic patients. However, with severely impaired liver function, there may be marked prolongation of quinidine half-life predisposing to quinidine toxicity. The possible clinical implications of these findings are discussed.

Original languageEnglish (US)
Pages (from-to)708-715
Number of pages8
JournalAmerican Heart Journal
Volume98
Issue number6
DOIs
StatePublished - 1979
Externally publishedYes

Fingerprint

Quinidine
Cardiac Arrhythmias
Pharmacokinetics
Therapeutics
Half-Life
Hepatic Insufficiency
Alcoholics
Dilatation
High Pressure Liquid Chromatography
Liver
Serum

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Carliner, N. H., Crouthamel, W. G., Fisher, M. L., Mugmon, M. A., Vassar, D. L., Narang, P. K., & Plotnick, G. D. (1979). Quinidine therapy in hospitalized patients with ventricular arrhythmias. American Heart Journal, 98(6), 708-715. https://doi.org/10.1016/0002-8703(79)90467-8

Quinidine therapy in hospitalized patients with ventricular arrhythmias. / Carliner, Nathan H.; Crouthamel, William G.; Fisher, Michael L.; Mugmon, Marc A.; Vassar, Dean L.; Narang, Prem K.; Plotnick, Gary D.

In: American Heart Journal, Vol. 98, No. 6, 1979, p. 708-715.

Research output: Contribution to journalArticle

Carliner, NH, Crouthamel, WG, Fisher, ML, Mugmon, MA, Vassar, DL, Narang, PK & Plotnick, GD 1979, 'Quinidine therapy in hospitalized patients with ventricular arrhythmias', American Heart Journal, vol. 98, no. 6, pp. 708-715. https://doi.org/10.1016/0002-8703(79)90467-8
Carliner NH, Crouthamel WG, Fisher ML, Mugmon MA, Vassar DL, Narang PK et al. Quinidine therapy in hospitalized patients with ventricular arrhythmias. American Heart Journal. 1979;98(6):708-715. https://doi.org/10.1016/0002-8703(79)90467-8
Carliner, Nathan H. ; Crouthamel, William G. ; Fisher, Michael L. ; Mugmon, Marc A. ; Vassar, Dean L. ; Narang, Prem K. ; Plotnick, Gary D. / Quinidine therapy in hospitalized patients with ventricular arrhythmias. In: American Heart Journal. 1979 ; Vol. 98, No. 6. pp. 708-715.
@article{3b9c0311954841d6903c841f61e90443,
title = "Quinidine therapy in hospitalized patients with ventricular arrhythmias",
abstract = "Quinidine serum levels and pharmacokinetic data were assessed during steady state therapy with oral quinidine sulfate in 19 hospitalized patients who were being treated for ventricular arrhythmias. A new high performance liquid chromatography assay was employed. Four patients were studied both after the first dose of quinidine and at steady state, and the initial dose pharmacokinetic values were found not to be predictive of steady state. The mean half-life of quinidine was 4.5 hours, but there was wide individual variation. The elimination rate constant for quinidine was significantly lower in patients with echocardiographic evidence of left ventricular dilatation than in patients with normal echocardiographic left ventricular size. The average urinary excretion of quinidine was only 11.3{\%}. The pharmacokinetic data in seven chronic alcoholic patients without clinical or laboratory evidence of hepatic insufficiency did not differ from the data obtained in nonalcoholic patients. However, with severely impaired liver function, there may be marked prolongation of quinidine half-life predisposing to quinidine toxicity. The possible clinical implications of these findings are discussed.",
author = "Carliner, {Nathan H.} and Crouthamel, {William G.} and Fisher, {Michael L.} and Mugmon, {Marc A.} and Vassar, {Dean L.} and Narang, {Prem K.} and Plotnick, {Gary D.}",
year = "1979",
doi = "10.1016/0002-8703(79)90467-8",
language = "English (US)",
volume = "98",
pages = "708--715",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Quinidine therapy in hospitalized patients with ventricular arrhythmias

AU - Carliner, Nathan H.

AU - Crouthamel, William G.

AU - Fisher, Michael L.

AU - Mugmon, Marc A.

AU - Vassar, Dean L.

AU - Narang, Prem K.

AU - Plotnick, Gary D.

PY - 1979

Y1 - 1979

N2 - Quinidine serum levels and pharmacokinetic data were assessed during steady state therapy with oral quinidine sulfate in 19 hospitalized patients who were being treated for ventricular arrhythmias. A new high performance liquid chromatography assay was employed. Four patients were studied both after the first dose of quinidine and at steady state, and the initial dose pharmacokinetic values were found not to be predictive of steady state. The mean half-life of quinidine was 4.5 hours, but there was wide individual variation. The elimination rate constant for quinidine was significantly lower in patients with echocardiographic evidence of left ventricular dilatation than in patients with normal echocardiographic left ventricular size. The average urinary excretion of quinidine was only 11.3%. The pharmacokinetic data in seven chronic alcoholic patients without clinical or laboratory evidence of hepatic insufficiency did not differ from the data obtained in nonalcoholic patients. However, with severely impaired liver function, there may be marked prolongation of quinidine half-life predisposing to quinidine toxicity. The possible clinical implications of these findings are discussed.

AB - Quinidine serum levels and pharmacokinetic data were assessed during steady state therapy with oral quinidine sulfate in 19 hospitalized patients who were being treated for ventricular arrhythmias. A new high performance liquid chromatography assay was employed. Four patients were studied both after the first dose of quinidine and at steady state, and the initial dose pharmacokinetic values were found not to be predictive of steady state. The mean half-life of quinidine was 4.5 hours, but there was wide individual variation. The elimination rate constant for quinidine was significantly lower in patients with echocardiographic evidence of left ventricular dilatation than in patients with normal echocardiographic left ventricular size. The average urinary excretion of quinidine was only 11.3%. The pharmacokinetic data in seven chronic alcoholic patients without clinical or laboratory evidence of hepatic insufficiency did not differ from the data obtained in nonalcoholic patients. However, with severely impaired liver function, there may be marked prolongation of quinidine half-life predisposing to quinidine toxicity. The possible clinical implications of these findings are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0018576137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018576137&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(79)90467-8

DO - 10.1016/0002-8703(79)90467-8

M3 - Article

C2 - 495420

AN - SCOPUS:0018576137

VL - 98

SP - 708

EP - 715

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 6

ER -